Evidence map›Paper›PMID 34125004›Full record

ArticleBioengineered2021

The expression and clinical prognostic value of protein phosphatase 1 catalytic subunit beta in pancreatic cancer.

Lingyu Hu, Haokai Xu, Xiaoguang Wang, Bin Wu, Fei Chen, Wei Chen, Yong Gao, Zhengxiang Zhong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lingyu HuBengbu Medical College, Bengbu, Anhui P.R. China.
Haokai XuBengbu Medical College, Bengbu, Anhui P.R. China.
Xiaoguang WangDepartment of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang P.R. China.
Bin WuDepartment of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang P.R. China.
Fei ChenDepartment of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang P.R. China.
Wei ChenCancer Institute of Integrated Traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, P.R. China.
Yong GaoBengbu Medical College, Bengbu, Anhui P.R. China.
Zhengxiang ZhongBengbu Medical College, Bengbu, Anhui P.R. China.ORCID 0000-0003-2270-4140
Bengbu Medical College · CNJiaxing University · CNTongde Hospital of Zhejiang Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer (PAAD) is a common malignancy with a poor survival rate. The identification of novel biomarkers could improve clinical outcomes for patients with PAAD. Here we evaluated the expression and clinical significance of

Indexed as

Pancreatic NeoplasmsBiomarkers, TumorComputational BiologyFemaleHumansMaleMiddle AgedPrognosisProtein Phosphatase 1TranscriptomeBiomarkers, TumorPPP1CB protein, humanProtein Phosphatase 1Bioinformatics analysispancreatic adenocarcinomaprognosisprotein phosphatase 1 catalytic subunit beta

Identifiers

PMID34125004
PMCPMC8806868
OpenAlexW3171728976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.